Lineage Cell’s OpRegen study shows rapid improvements to outer retinal structure

Lineage Cell Therapeutics (LCTX) announced that the results of imaging analyses demonstrating rapid improvement in outer retinal structure from patients enrolled in a Phase 1/2a clinical study of RG6501, OpRegen, which were reviewed by multiple, independent reviewers, were presented at the 23rd EURETINA Congress. The presentation, “Time to retinal structure improvements following OpRegen subretinal delivery in patients with geographic atrophy ” was presented by Adiel Barak, M.D., Professor of Ophthalmology, Vitreoretinal Unit Director, Tel Aviv Medical Center, on behalf of Roche (RHHBY) and Genentech, a member of the Roche Group. “We are extremely pleased to see these additional observations of rapid improvements to outer retinal structure in the initial clinical study of OpRegen. These data suggest that OpRegen RPE cells may provide direct support to the patients’ remaining retinal cells within atrophic areas, and that the improvements to retinal structure can be detected within the first three months following a single administration. We look forward to additional, future clinical data updates on the OpRegen program from our partners, Roche and Genentech,” stated Brian Culley, CEO of Lineage.